Amgen to Present 10 Abstracts from its Dermatology Portfolio at the 73rd Annual Meeting of the AAD
Amgen will present data from multiple brodalumab and Enbrel (etanercept) studies at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco, 20–24 March 2015. The breadth of data to be presented highlights Amgen's long-term commitment to advancing innovative treatment options for patients with serious, chronic dermatologic diseases.
"Patients with psoriasis struggle on a daily basis with the serious symptoms of the disease, and we are excited to share research findings at this year's AAD meeting that highlight our continued commitment to advancing science to help these patients," said Sean E. Harper, executive vice president of R&D at Amgen. "Results from our Phase III brodalumab clinical trial program draw on research from more than 4200 patients and provide important insights on safety and efficacy of this IL-17 receptor inhibitor in moderate-to-severe plaque psoriasis, while new Enbrel data offer perspectives on use and adherence in a real-world setting."
Data to be presented include results from all three of the brodalumab Phase III Amagine pivotal trials, evaluating the efficacy and safety of the IL-17 receptor inhibitor in patients with moderate-to-severe plaque psoriasis from the induction through the maintenance phase through week 52. Additional brodalumab long-term data from the Phase 2IIopen-label extension study provide further insights on the maintenance of clinical response with long-term brodalumab therapy in patients with moderate-to-severe psoriasis. Brodalumab is being co-developed by Amgen and AstraZeneca.
Kyowa Hakko Kirin, which has an exclusive licence to develop and commercialise brodalumab in Japan, China and certain other Asian countries, will present additional, long-term Phase III brodalumab efficacy and safety data from its open-label extension study in Japanese patients with moderate-to-severe plaque psoriasis.
Enbrel data provide insights from OBSERVE-5, an observational registry designed to examine the use of Enbrel in a real-world setting over five years, as well as on treatment patterns with Enbrel compared with other agents in US veterans with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Additional data to be presented will look at patient-reported psoriasis symptom severity using the Psoriasis Symptom Inventory (PSI) scale compared to Physician Global Assessment results.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance